Melanoma | Clinical

Early Efficacy of Darovasertib +/- Binimetinib Better Than Historical Controls for Metastatic Uveal Melanoma

April 16, 2021

Darovasertib, a selective protein kinase C inhibitor, demonstrated promising response rates, survival, and reduction in tumor size as treatment of patients with metastatic uveal melanoma treatment both alone and in combination with binimetinib, according to preliminary results from a 7-armed phase 1/2 clinical trial.